Graves’ disease in HIV patient receiving antiretroviral therapy
https://doi.org/10.14341/probl12375
Abstract
The article focuses on the clinical case of Graves’ disease in a patient with HIV infection who is receiving antiretroviral therapy. The number of HIV-infected patients has increased significantly in recent decades all over the world. The currently used highly active antiretroviral therapy can significantly improve the prognosis for these patients. However, its use is associated with a number of complications, in particular the development of immune reconstitution syndrome, under which the development of such autoimmune diseases as Graves’ disease, polymyositis and Guillain-Barre syndrome may occur. Therefore, we would like to draw the attention of doctors to the possibility of such a complication in patients receiving antiretroviral therapy. Timely diagnosis and treatment of thyroid disorders will help to avoid the complications associated with an excess or deficit of thyroid hormones.
About the Authors
Tatyana B. MorgunovaRussian Federation
MD, PhD
Anastasia A. Zorina
Russian Federation
Ekaterina S. Maloletkina
Russian Federation
MD
Yulia P. Sytch
Russian Federation
MD, PhD
Ariadna V. Vasileva
Russian Federation
MD
Valentin V. Fadeyev
Russian Federation
MD, PhD, Professor
References
1. Roszkiewicz J, Smolewska E. Kaleidoscope of autoimmune diseases in HIV infection. Rheumatol Int. 2016;36(11):1481−1491. doi: 10.1007/s00296-016-3555-7.
2. Chen F, Day SL, Metcalfe RA, et al. Characteristics of autoimmune thyroid disease occurring as a late complication of immune reconstitution in patients with advanced human immunodeficiency virus (HIV) disease. Medicine (Baltimore). 2005;84(2):98−106. doi: 10.1097/01.md.0000159082.45703.90.
3. Jubault V, Penfornis A, Schillo F, et al. Sequential occurrence of thyroid autoantibodies and Graves’ disease after immune restoration in severely immunocompromised human immunodeficiency virus-1-infected patients. J Clin Endocrinol Metab. 2000;85(11):4254−4257. doi: 10.1210/jcem.85.11.6988.
4. Rasul S, Delapenha R, Farhat F, et al. Graves’ disease as a manifestation of immune reconstitution in HIV-Infected individuals after initiation of highly active antiretroviral therapy. AIDS Res Treat. 2011;2011:743597. doi: 10.1155/2011/743597.
5. Hsu E, Phadke VK, Nguyen ML. Short communication: hyperthyroidism in human immunodeficiency virus patients on combined antiretroviral therapy: case series and literature review. AIDS Res Hum Retroviruses. 2016;32(6):564−566. doi: 10.1089/AID.2015.0374.
6. Muller I, Moran C, Lecumberri B, et al. 2019 European thyroid association guidelines on the management of thyroid dysfunction following immune reconstitution therapy. Eur Thyroid J. 2019;8(4):173−185. doi: 10.1159/000500881.
7. Silva GA, Andrade MC, Sugui Dde A, et al. Association between antiretrovirals and thyroid diseases: a cross-sectional study. Arch Endocrinol Metab. 2015;59(2):116−122. doi: 10.1590/2359-3997000000023.
8. Weetman AP. Thyroid abnormalities. Endocrinol Metab Clin North Am. 2014;43(3):781−790. doi: 10.1016/j.ecl.2014.05.006.
9. French MA, Lewin SR, Dykstra C, et al. Graves’ disease during immune reconstitution after highly active antiretroviral therapy for HIV infection: evidence of thymic dysfunction. AIDS Res Hum Retroviruses. 2004;20(2):157−162. doi: 10.1089/088922204773004879.
Supplementary files
Review
For citations:
Morgunova T.B., Zorina A.A., Maloletkina E.S., Sytch Yu.P., Vasileva A.V., Fadeyev V.V. Graves’ disease in HIV patient receiving antiretroviral therapy. Problems of Endocrinology. 2020;66(3):22-26. (In Russ.) https://doi.org/10.14341/probl12375

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).